Document is current
Any future updates will be listed below
-
Authors
Paulsen, Bruna http://orcid.org/0000-0001-5304-0610
Velasco, Silvia http://orcid.org/0000-0003-0638-0932
Kedaigle, Amanda J. http://orcid.org/0000-0001-6156-5046
Pigoni, Martina http://orcid.org/0000-0002-7896-6978
Quadrato, Giorgia http://orcid.org/0000-0003-0717-4874
Deo, Anthony J.
Adiconis, Xian
Uzquiano, Ana
Sartore, Rafaela
Yang, Sung Min
Simmons, Sean K.
Symvoulidis, Panagiotis http://orcid.org/0000-0002-1396-3426
Kim, Kwanho http://orcid.org/0000-0002-4448-3193
Tsafou, Kalliopi
Podury, Archana
Abbate, Catherine
Tucewicz, Ashley
Smith, Samantha N.
Albanese, Alexandre
Barrett, Lindy http://orcid.org/0000-0002-3229-4774
Sanjana, Neville E.
Shi, Xi
Chung, Kwanghun http://orcid.org/0000-0002-8167-3340
Lage, Kasper http://orcid.org/0000-0001-6827-6239
Boyden, Edward S.
Regev, Aviv
Levin, Joshua Z. http://orcid.org/0000-0002-0170-3598
Arlotta, Paola http://orcid.org/0000-0003-2184-2277
- License Information
-
More Information
Article History
Received: 2 November 2020
Accepted: 14 December 2021
First Online: 2 February 2022
Competing interests
: P.A. is a SAB member at Herophilus, Foresite Labs, and Rumi Scientific, a consultant for the New York Stem cell Foundation, and is a co-founder of esalius Therapeutics. A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and, until 31 August 2020, was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From 1 August 2020, A.R. is an employee of Genentech. N.E.S. is an advisor to Vertex and Qiagen.
